ImmuCell (ICCC) Competitors

GENFIT (NASDAQ:GNFT) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Do institutionals & insiders have more ownership in GNFT or ICCC?

2.2% of GENFIT shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 4.2% of GENFIT shares are held by company insiders. Comparatively, 5.6% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has higher earnings & valuation, GNFT or ICCC?

GENFIT has higher revenue and earnings than ImmuCell.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENFIT	$67.00M	3.01	$1.63M	N/A	N/A
ImmuCell	$28.27M	1.96	-$2.16M	$0.19	32.21

Does the media refer more to GNFT or ICCC?

In the previous week, GENFIT had 1 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for GENFIT and 3 mentions for ImmuCell. GENFIT's average media sentiment score of 1.08 beat ImmuCell's score of 1.07 indicating that GENFIT is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GENFIT	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuCell	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, GNFT or ICCC?

GENFIT has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Do analysts prefer GNFT or ICCC?

GENFIT currently has a consensus price target of $9.00, suggesting a potential upside of 123.33%. Given GENFIT's stronger consensus rating and higher possible upside, research analysts plainly believe GENFIT is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GENFIT	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ImmuCell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is GNFT or ICCC more profitable?

ImmuCell has a net margin of 6.23% compared to GENFIT's net margin of 0.00%. ImmuCell's return on equity of 6.25% beat GENFIT's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENFIT	N/A	N/A	N/A
ImmuCell	6.23%	6.25%	3.87%

Summary

GENFIT beats ImmuCell on 9 of the 14 factors compared between the two stocks.